CA
NZ
UK
AU
IND
US
Mesoblast (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines, has announced a major milestone for its FDA-approved mesenchymal stromal cell (MSC) therapy, Ryoncil® (remestemcel-L). The company has entered into a National Drug Rebate Agreement (NDRA) with the U.S. Centers for Medicare & Medicaid …
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing and manufacturing authorization for Dupixent® (dupilumab) to treat chronic obstructive pulmonary disease (COPD) in adults whose condition is not well-managed with existing therapies. This …
Innate Pharma SA (Nasdaq:IPHA)has announced its financial results for the year ending December 31, 2024, alongside notable advancements in its clinical pipeline. The company continues to make progress in immuno-oncology, securing regulatory recognition and funding to support ongoing research efforts.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced significant progress in the development of its proprietary antisense oligonucleotide (ASO) drug candidate, HT-KIT. The biopharmaceutical company is focused on creating therapies for allergic and inflammatory diseases, and HT-KIT represents an innovative approach to treating conditions such …
Entero Therapeutics, Inc. (NASDAQ:ENTO), a clinical-stage biopharmaceutical company specializing in targeted therapies for gastrointestinal diseases, has successfully reached an agreement to rescind its previously completed business combination with ImmunogenX, LLC. The rescission agreement, signed with all former ImmunogenX shareholders, is subject to certain conditions, …
Opthea Limited (NASDAQ:OPT), a clinical-stage biopharmaceutical company, has announced the results of its global Phase 3 COAST (Combination OPT-302 with Aflibercept Study) trial, which evaluated the combination therapy of sozinibercept and aflibercept for the treatment of wet age-related macular degeneration (wet AMD). The trial …
Please wait processing your request...